Then, rNDV-TV-Rux, which improved rNDV infection rate in ruxolitinib, increased CD8 + cells important for inducing anti-tumor response by this tumor vaccine and induced a Th1 immune response compared to rNDV-TV. The gene discussed is CD8A; the disease is neoplasm.